...
首页> 外文期刊>Pharmaceutical patent analyst >Opposing a granted patent in the USA: post grant and inter partes review
【24h】

Opposing a granted patent in the USA: post grant and inter partes review

机译:反对美国授予专利:授予授权和临时审查

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Although contentious, interpartes administrative proceedings to oppose a granted patent have been available for a long time in Europe and other jurisdictions, similar proceedings are relatively new in the USA. Historically, a party seeking to invalidate an issued USA patent at the United States Patent and Trademark Office (PTO) was limited to filing a request for exparte reexamination (EPR). However, other than preparing an initial request for an EPR and a reply to the patent owner (if the patent owner responds to the request), such proceedings were and continue to be exparte, and thus do not permit further participation by the party seeking to invalidate the patent [i].The USA broadened the options to challenge an issued patent in 2000 by enacting a procedure called inter partes re-examination, which permitted further participation by the challenging party [2,3]. Inter partes re-examination proceedings were replaced by inter partes review (IPR) proceedings in 2012, by sweeping changes to USA patent law under the America Invents Act, and have grown in popularity since its inception. As of January 2019, a total of 9031 IPRs have been filed [4]. The grounds for challenging validity are limited for both IPRs and EPRs to anticipation and obviousness based on patents and printed publications [5]. However, in contrast to EPRs, IPRs permit a party to not only file a petition with the PTO, but also to fully participate in invalidity proceedings, including through discovery and an administrative trial.The America Invents Act also created a third alternative to challenging issued patents, post grant review (PGR). While IPRs have been widely used, PGRs are just starting to gain momentum, in part because the procedure is available only for patents with an effective filing date on or after 16 March 2013 [6]. Unlike EPRs and IPRs, a PGR must be filed within 9 months after the issuance of a patent, so a decision to file a PGR needs to be made promptly after a patent issues [7]. This article compares the differences between PGR and IPR to facilitate considerations for choosing between them.
机译:虽然有争议的互联网行政程序在欧洲和其他司法管辖区中有很长一段时间可用,但在美国相似的诉讼程序中是相对较新的。从历史上看,寻求使美国专利和商标局(PTO)在美国专利和商标办公室(PTO)的派对被限制为提交effare再审(EPR)的请求。但是,除了为EPR准备初始请求和对专利所有人的答复之外(如果专利所有者响应请求),则此类诉讼程序并继续进行,因此不允许派对进一步参与派对使专利[i]无效。美国通过制定被称为党派重新审查的程序来挑战2000年发布专利的选项,该计划允许通过挑战党进一步参与[2,3]。国际党派党员重新审查程序被审查审查(知识产权)审查(知识产权)议程审查,2012年通过美国专利法根据美国投资法案的改变,自成立以来已普及。截至2019年1月,共提出了9031个知识产权[4]。有效性的基础是知识产权和EPRS的限制,以基于专利和印刷出版物的预期和显而易见[5]。然而,与EPRS相比,知识产权允许缔约方不仅提出与PTO的申请,而且还要充分参与无效程序,包括通过发现和行政审判。美国投资法案也创造了发布的挑战的第三种选择专利,授予授权审查(PGR)。虽然IPRS已被广泛使用,但PGRS刚刚开始获得势头,部分原因是只有在2013年3月16日或之后的专利仅适用于有效申请日期的专利[6]。与EPRS和IPRS不同,必须在颁发专利后9个月内提交PGR,因此在专利问题后,需要迅速提出提交PGR的决定[7]。本文比较了PGR与IPR之间的差异,以方便考虑在它们之间进行选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号